Veracyte, Inc. (VCYT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$42.53-4.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improves to sustain growth: metric not reported.
Veracyte grows revenue about 13% yearly, driven by new tests. Profit rises with better cost control, shown by operating income up from $2.9M to $22.6M. Cash from operations jumped from $5.4M to $35.2M, supporting growth and investments.
Growth could slow if new product launches fail or market competition intensifies. Profit margins may shrink if costs rise faster than revenue. Cash flow might weaken if operational efficiencies stall.
The price is about 15% above our fair value near $49, reflecting roughly 14% revenue growth expected by analysts. Our fair value is below the Street median, suggesting some caution despite strong growth.
Breaks if: Cash from operations falls below $30M over next year
Generate strong operating cash flow to support growth and investments.
Stated in 4 of last 4 quarters. Cash from operations grew from $33.6 million in 2025-Q2 to $45.8 million in 2026-Q2, showing consistent improvement. Management's focus on cash generation is reflected in the steady increase in operating cash flow, delivering on this priority.
“Generated $45.8 million of cash from operations in Q2 2026.”
“Generated $35.2 million of cash from operations in Q1 2026.”
“Generated $52.6 million of cash from operations in Q4 2025.”
“Generated $44.8 million of cash from operations in Q3 2025.”
Breaks if: Operating income falls below prior year levels or turns negative
Improve operating income through cost management and revenue growth.
Breaks if: Revenue falls below $570M in FY26
Continue driving double-digit growth in total and testing revenue through core products and new launches.
Stated as a priority in 4 of last 4 quarters. Total revenue grew from $130.2 million in 2025-Q2 to $150.3 million in 2026-Q2 (+15%), with testing revenue up 19% to $145.7 million in 2026-Q2. Management consistently emphasized double-digit revenue growth, and the financials show delivering on this trajectory.
“Grew total revenue to $150.3 million, an increase of 15% compared to Q2 2025.”
“Increased total revenue by 21% to $139.1 million compared to Q1 2025.”
“Increased total revenue by 19% to $140.6 million compared to Q4 2024.”
“Revenue grew to $131.9 million, up from $130.2 million in Q2 2025.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and profitability. The current thesis is intact, supported by strong recent financial performance, but there are risks that could impact future results.
The market seems to have priced in a premium compared to peers, reflecting justified expectations based on recent performance. However, there is a gap in expectations, indicating that the market may be cautious about future guidance.
Management is on track to achieve its goals of increasing revenue, enhancing profitability, and boosting cash from operations. Recent financial results show strong growth, but there is a low probability of missing future estimates, which could create volatility.
The thesis hinges on management's ability to maintain guidance and the overall health of the healthcare sector. Key factors include the performance of sector leaders and broader economic indicators that could impact investor sentiment.
Over the next 1 to 3 years, VCYT's strong fundamentals are supported by management's focus, but external risks could influence its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.